Paul Forfia, MD, Co-Director of the Pulmonary Hypertension, Right Heart Failure & Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Temple University Hospital and Professor of Medicine at the Lewis Katz School of Medicine at Temple University, provided perspective for a Healio article about the decision to end the phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension (PAH) functional class two or three early due to robust positive evidence found in previous trials.
Weather Alert: Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH